ZBIO News

WALTHAM, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on December 15, 2025 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase 300,000 shares of the Company’s common stock to two newly hired employees of the Company as an inducement material to such employees’ entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).

NEW YORK, Nov. 20, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Zenas BioPharma, Inc. (NASDAQ: ZBIO) on behalf of the company's shareholders. The investigation seeks to determine whether Zenas BioPharma's directors breached their fiduciary duties in...

WALTHAM, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for autoimmune diseases, today announced management’s presentations at the following investor conferences in September:

NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. (Zenas BioPharma, Inc. or the Company) (NASDAQ: ZBIO) of a class action securities lawsuit.

NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. (Zenas BioPharma, Inc. or the Company) (NASDAQ: ZBIO) of a class action securities lawsuit.

LOS ANGELES--(BUSINESS WIRE)---- $ZBIO--ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)---- $ZBIO--ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm

NEW YORK--(BUSINESS WIRE)---- $ZBIO #BioPharma--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Zenas BioPharma, Inc. (“Zenas” or the “Company”) (NASDAQ: ZBIO) and reminds investors of the June 16, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm

NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO).

NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO).